SDZXF (Sandoz Group AG) ROE % Adjusted to Book Value: 3.48% (As of Dec. 2025)


SDZXF Sandoz Group AG SDZXF
18 GF Score
Price $89.55
! 6 Warning Signs
View Full Analysis

What is Sandoz Group AG ROE % Adjusted to Book Value?

Sandoz Group AG SDZXF 18 ROE % Adjusted to Book Value is 3.48% as of Dec. 2025. GuruFocus rates SDZXF with a GF Score™ of 18/100. The stock has 6 warning signs investors should review.

Sandoz Group AG's ROE % for the quarter that ended in Dec. 2025 was 11.80%. Sandoz Group AG's PB Ratio for the quarter that ended in Dec. 2025 was 3.39. Sandoz Group AG's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was 3.48%.

Sandoz Group AG ROE % Adjusted to Book Value Related Terms

Sandoz Group AG ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Sandoz Group AG's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sandoz Group AG ROE % Adjusted to Book Value Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.55 0.00 3.07

Sandoz Group AG Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial -2.27 1.89 -1.67 3.50 3.48

SDZXF vs ZTS, UTHR, VTRS: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sandoz Group AG ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Sandoz Group AG's ROE % Adjusted to Book Value falls into.


SDZXF
18GF Score
Sandoz Group AG SDZXF
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sandoz Group AG ROE % Adjusted to Book Value Calculation

Sandoz Group AG's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=10.42% / 3.39
=3.07%

Sandoz Group AG's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=11.80% / 3.39
=3.48%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 3.48% mean?
Sandoz Group AG (SDZXF) has a ROE % Adjusted to Book Value of 3.48% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Sandoz Group AG and its competitors.
Is Sandoz Group AG's ROE % Adjusted to Book Value too high?
Sandoz Group AG's current ROE % Adjusted to Book Value is 3.48%. Overall, Sandoz Group AG has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's ROE % Adjusted to Book Value compare to ZTS and UTHR?
Sandoz Group AG's ROE % Adjusted to Book Value of 3.48% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Sandoz Group AG and its competitors. Sandoz Group AG's current ROE % Adjusted to Book Value is 3.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Sandoz Group AG (SDZXF) has a current ROE % Adjusted to Book Value of 3.48%. The current ROE % Adjusted to Book Value is 3.48%. Sandoz Group AG's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Sandoz Group AG (SDZXF), the current ROE % Adjusted to Book Value is 3.48% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sandoz Group AG Business Description

Address Centralbahnstrasse 4, Basel, CHE, 4051
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
18GF Score

Get the complete analysis for SDZXF

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$89.55
Price